Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

PREDICT-RD: ctDNA surveillance in TNBC with residual disease

Phase 2 study in stage II or III triple-negative breast cancer with residual disease after neoadjuvant therapy. The registry primary outcome is the proportion with molecular residual disease. ClinicalTrials.gov lists the study as recruiting.

UNC Lineberger Comprehensive Cancer Center